title: Leptin measurement in urine is a reliable method of monitoring its secretion in patients with obstructive sleep apnea syndrome.
abstract: Leptin is believed to play a significant role in the pathogenesis of obstructive sleep apnea syndrome (OSAS) as well as progression of OSAS-related obesity. It is also known that other factors such as gender and diurnal variations in serum strongly affect the measurement results making repeated blood sampling necessary for leptin precise monitoring. Since renal metabolism and urine secretion are the main elimination mechanism for leptin, in this study we evaluated urine relevance for leptin secretion monitoring. Serum and urine (collected during the day and overnight) sampled from 169 OSAS patients and 41 controls were assayed by immunoenzymatic method specific for human leptin. Only 5 (17%) controls and 10 (5.8%) OSAS patients had undetectable urine leptin. We observed significant relationships between serum and urinary leptin in both day-time (r=0.656, P<0.001) and night-time (r=0.518, P<0.001) samples and between day and night-time urine leptin (r=0.811, P<0.001). Significance values did not alter when urinary leptin levels were expressed as the ratio to urinary creatinine. Gender-related differences in leptin concentrations were present both in serum (P<0.001) and overnight urine (P<0.01) in the OSAS group. However, mean night-time urine leptin was lower in the OSAS patients (P<0.05) and their subgroups stratified according to disease severity (P<0.01), while serum leptin levels were comparable in both groups. We conclude that assaying leptin in urine by immunoenzymatic method is a reliable and useful non-invasive alternative for its serum measurement. However, night-time urine leptin levels better reflect differences in its turnover due to gender and OSAS severity.
authors.affiliation: Laboratory of Molecular Diagnostics, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland. j.chorostowska@igichp.edu.pl
authors.forename: J
authors.initials: J
authors.lastname: Chorostowska-Wynimko
authors.forename: R
authors.initials: R
authors.lastname: Pływaczewski
authors.forename: L
authors.initials: L
authors.lastname: Jończak
authors.forename: M
authors.initials: M
authors.lastname: Bednarek
authors.forename: A
authors.initials: A
authors.lastname: Stepniewska
authors.forename: A
authors.initials: A
authors.lastname: Borowska
authors.forename: D
authors.initials: D
authors.lastname: Gorecka
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000652:urine; D016022:Case-Control Studies; D002940:Circadian Rhythm; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D020738:Leptin / Q000097:blood / Q000652:urine*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D012720:Severity of Illness Index; D012737:Sex Factors; D020181:Sleep Apnea, Obstructive / Q000097:blood / Q000652:urine*
chemical_list: D015415:Biomarkers; D020738:Leptin